An oral fluoropyrimidine prodrug with activity in colorectal cancer

Conclusions

The authors conclude that capecitabine offers a new and effective treatment option as an oral single agent for advanced colorectal carcinoma. Response rates of over 20% were seen for all groups, and the addition of leucovorin did not appear to have a marked effect on outcome except for toxicity. The intermittent single-agent capecitabine schedule was chosen for further phase III evaluation based on toxicity, dose intensity, response rate, and time to progression.